Integrated transcriptomics prioritizes cell types and genes associated with MASH fibrosis
Source check: Source checked. Not independent scientific confirmation.
Finding: Junjie Zhang and colleagues at Gannan Medical University and affiliated institutions combined four bulk RNA-sequencing datasets, a single-nucleus liver dataset and machine-learning feature selection to identify fibrosis-associated genes and cell populations in metabolic dysfunction-associated steatohepatitis (MASH). They report a seven-gene signature with AUC 0.81 (95% CI 0.69–0.93) in an independent cohort, and qRT-PCR checks of selected genes in a methionine-choline-deficient mouse model. These results support candidate associations; mouse expression checks do not establish causal mechanisms or clinical utility.
Technology: Robust rank aggregation, WGCNA and machine-learning feature selection with single-nucleus RNA sequencing
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Machine-learning feature selection prioritized fibrosis-associated genes from integrated bulk transcriptomics; single-nucleus analysis characterized cell populations and qRT-PCR checked selected expression in mice.
- Test and result
- A seven-gene signature achieved AUC 0.81 (95% CI 0.69–0.93) in an independent cohort within the study; selected expression directions were checked by qRT-PCR in a MASH mouse model.
- Limitation / still unknown
- Gene associations and mouse expression validation do not establish causality, therapeutic effect or clinical utility.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2026.1961567/full
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary source full text reviewed for title, authorship, Methods, Results, version date and stated limitations..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.